Standout Papers

Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results ... 2023 2026 202499
  1. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial (2023)
    Richard Lafayette, Jens Kristensen et al. The Lancet

Immediate Impact

1 by Nobel laureates 51 standout
Sub-graph 1 of 24

Citing Papers

Strategies to reduce the risks of mRNA drug and vaccine toxicity
2024 Standout
mRNA-based therapeutics: looking beyond COVID-19 vaccines
2024 StandoutNobel
1 intermediate paper

Works of Hernán Trimarchi being referenced

The Kidney in Fabry Disease
2016

Author Peers

Author Last Decade Papers Cites
Hernán Trimarchi 988 282 191 317 296 109 1.6k
C. Frederic Strife 766 247 71 217 252 63 1.8k
Yoshio Taguma 1164 300 111 326 228 95 2.0k
Eduardo Gutiérrez 1119 348 64 259 317 85 1.9k
L Minetti 867 182 61 188 180 90 1.7k
Gastón Zilleruelo 1011 232 81 264 132 76 2.0k
Damien Noone 808 164 89 158 322 69 1.3k
Takahito Moriyama 1136 256 62 399 191 100 1.5k
N.P. Mallick 924 125 119 186 156 66 1.9k
Osamu Hotta 1017 312 140 369 295 100 1.7k
É. Alamartine 1002 193 70 204 250 80 2.0k

All Works

Loading papers...

Rankless by CCL
2026